AML_targeted_resequencing_study - EGA European Genome-Phenome Archive

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001000253	AML targeted resequencing study	Illumina HiSeq 2000	-
EGAD00001000283	Agilent whole exome hybridisation capture was performed on genomic DNA derived from MDS and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to discover the prevalence of our findings using bespoke pulldown methods and sequencing the products from a larger set of patient DNA.	Illumina HiSeq 2000	764

Publications	Citations
Genomic Classification and Prognosis in Acute Myeloid Leukemia. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ. N Engl J Med 374: 2016 2209-2221	2510
Precision oncology for acute myeloid leukemia using a knowledge bank approach. Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Nat Genet 49: 2017 332-340	159
Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia. Prochazka KT, Pregartner G, Rücker FG, Heitzer E, Pabst G, Wölfler A, Zebisch A, Berghold A, Döhner K, Sill H. Haematologica 104: 2019 516-523	59
AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. Yan B, Claxton D, Huang S, Qiu Y. Exp Hematol 87: 2020 13-19	21
Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Benard BA, Leak LB, Azizi A, Thomas D, Gentles AJ, Majeti R. Nat Commun 12: 2021 7244	41
Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML. Batcha AMN, Buckup N, Bamopoulos SA, Jurinovic V, Rothenberg-Thurley M, Gittinger H, Ksienzyk B, Dufour A, Schneider S, Kontro M, Saad J, Heckmann CA, Sauerland C, Görlich D, Berdel WE, Wörmann BJ, Krug U, Braess J, Mansmann U, Hiddemann W, Spiekermann K, Metzeler KH, Herold T. Blood Adv 7: 2023 1040-1044	0